Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05268224Unknown

A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue

Role: lead

NCT04974567Unknown

Tear Based Sample Collection Breast Cancer Detection

Role: lead

NCT04928014Unknown

Validation of a Tear-based Screening Assay for Breast Cancer

Role: lead

NCT05223218Unknown

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

Role: lead

NCT04542980Completed

Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19

Role: lead

All 5 trials loaded